AAM
ENTA icon

Aureus Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Aureus Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-166,546
Closed -$4.89M – 135
2016
Q1 		$4.89M Buy
166,546
+10,397
+7% +$289K 1.07% 35
2015
Q4 		$5.16M Buy
+156,149
New +$5.09M 1.16% 34
2014
Q3 		– Sell
-55,530
Closed -$2.39M – 132
2014
Q2 		$2.39M Buy
+55,530
New +$2.12M 0.6% 46

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Aureus Asset Management's ENTA Position: Q2 2016 in Review

Aureus Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2016, closing a stake of 166,546 shares — an estimated $4.89M sold.

Aureus Asset Management first reported a position in ENTA in Q2 2014 and held it in 3 quarters. The position peaked at $5.16M in Q4 2015. 130 funds tracked by Wall St. Rank hold ENTA as of Q2 2016.

  • Aureus Asset Management reported no remaining Enanta Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Aureus Asset Management sold 166,546 Enanta Pharmaceuticals shares in Q2 2016, an estimated $4.89M.
  • Aureus Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Aureus Asset Management's Enanta Pharmaceuticals position peaked at $5.16M in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2016.

Based on Aureus Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.